Review





Similar Products

86
Servicebio Inc anti cd3 rabbit monoclonal antibody
Anti Cd3 Rabbit Monoclonal Antibody, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd3+monoclonal+antibody/anti+cd8%CE%B1/pmc12796584-169-10-16
Average 86 stars, based on 1 article reviews
anti cd3 rabbit monoclonal antibody - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

93
Proteintech primary rabbit anti human cd3 monoclonal antibody
Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for <t>CD3</t> + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
Primary Rabbit Anti Human Cd3 Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd3+monoclonal+antibody/Anti-human+CD3/pmc12776187-91-7-13
Average 93 stars, based on 1 article reviews
primary rabbit anti human cd3 monoclonal antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

98
Bio X Cell anti mouse cd3 mab
( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse <t>CD3</t> antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.
Anti Mouse Cd3 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd3+monoclonal+antibody/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pmc12646666-167-19-24
Average 98 stars, based on 1 article reviews
anti mouse cd3 mab - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

98
Bio X Cell mouse anti cd3
( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse <t>CD3</t> antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.
Mouse Anti Cd3, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd3+monoclonal+antibody/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pm40753778-89-15-17
Average 98 stars, based on 1 article reviews
mouse anti cd3 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc rabbit monoclonal antibody anti cd3
( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse <t>CD3</t> antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.
Rabbit Monoclonal Antibody Anti Cd3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd3+monoclonal+antibody/CD3+Rat+mAb/pmc12490235-29-0-5
Average 94 stars, based on 1 article reviews
rabbit monoclonal antibody anti cd3 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

98
Bio X Cell anti mouse cd3
a Schematic illustration of the treatment and analysis schedule for mice bearing orthotopic LLC tumors. b – f Representative flow cytometric analysis profiles and relative quantifications of CD8 + T cells (CD45 + <t>CD3</t> + CD8 + ) ( b ), Treg cells (CD45 + CD4 + FOXP3 + ) ( c ), MDSCs (CD45 + CD11b + Gr-1 + ) ( d ), IFN-γ-secreting CD8 + T cells (CD45 + CD3 + CD8 + IFN-γ + ) ( e ), and CD8 + T cell proliferation (CD45 + CD3 + CD8 + Ki67 + ) ( f ) within the TME following the indicated treatments. g – i Quantification of the infiltration of CD45 + immune cells ( g ), CD4 + T cells ( h ), and CD8 + T cells ( i ) into lung tumors using flow cytometry. j – n ELISA analysis of IFN-γ ( j ), IL-2 ( k ), IL-12p70 ( l ), TNF-α ( m ), and IL-10 ( n ) levels in lung tumors of mice following the indicated treatments. Flow cytometry gating strategies are shown in Supplementary Fig. . All data are from n = 5 mice and are presented as mean ± s.d. Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple comparisons test. P values as indicated. Source data are provided as a Source Data file.
Anti Mouse Cd3, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd3+monoclonal+antibody/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pmc12398490-297-31-36
Average 98 stars, based on 1 article reviews
anti mouse cd3 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

Image Search Results


Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

Journal: Translational Cancer Research

Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

doi: 10.21037/tcr-2025-707

Figure Lengend Snippet: Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

Techniques: Immunohistochemical staining, Staining, Immunofluorescence, Expressing, Flow Cytometry, Standard Deviation, Immunohistochemistry

( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse CD3 antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.

Journal: The Journal of Clinical Investigation

Article Title: Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes

doi: 10.1172/JCI176403

Figure Lengend Snippet: ( A ) RO NOD mice with blood glucose levels above 11.1 mmol/L were treated with anti–mouse CD3 antibody (2.5 μg/day) for 5 consecutive days. Blood glucose concentrations were monitored 3 times per week for 28 days following treatment initiation. At day 28, mice were classified as Rs or NRs on the basis of glycemic control. Pancreas and peripheral blood samples were collected at this time point for further analysis. ( B ) Kaplan-Meier survival curve shows the percentage of remission from disease of RO NOD mice after anti–mouse CD3 therapy. Black and white symbols indicate treated and untreated samples, respectively. ( C ) Individual glycemia levels of untreated mice, anti–mouse CD3 R mice, and anti–mouse CD3 NR mice during the study follow-up are shown in yellow, blue, and red, respectively. Normoglycemia threshold (11.1 mmol/L) is depicted by the red line. In B, the Mantel-Cox log-rank test was used for statistical comparison between groups.

Article Snippet: RO NOD mice were bled via the submandibular vein and treated for 5 consecutive days with 2.5 μg/d hamster anti–mouse CD3 mAb (clone 145-2C11, BioXCell) and monitored for a period of 28 days (CITE-Seq and follow-up) ( ).

Techniques: Control, Comparison

a Schematic illustration of the treatment and analysis schedule for mice bearing orthotopic LLC tumors. b – f Representative flow cytometric analysis profiles and relative quantifications of CD8 + T cells (CD45 + CD3 + CD8 + ) ( b ), Treg cells (CD45 + CD4 + FOXP3 + ) ( c ), MDSCs (CD45 + CD11b + Gr-1 + ) ( d ), IFN-γ-secreting CD8 + T cells (CD45 + CD3 + CD8 + IFN-γ + ) ( e ), and CD8 + T cell proliferation (CD45 + CD3 + CD8 + Ki67 + ) ( f ) within the TME following the indicated treatments. g – i Quantification of the infiltration of CD45 + immune cells ( g ), CD4 + T cells ( h ), and CD8 + T cells ( i ) into lung tumors using flow cytometry. j – n ELISA analysis of IFN-γ ( j ), IL-2 ( k ), IL-12p70 ( l ), TNF-α ( m ), and IL-10 ( n ) levels in lung tumors of mice following the indicated treatments. Flow cytometry gating strategies are shown in Supplementary Fig. . All data are from n = 5 mice and are presented as mean ± s.d. Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple comparisons test. P values as indicated. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA

doi: 10.1038/s41467-025-63415-0

Figure Lengend Snippet: a Schematic illustration of the treatment and analysis schedule for mice bearing orthotopic LLC tumors. b – f Representative flow cytometric analysis profiles and relative quantifications of CD8 + T cells (CD45 + CD3 + CD8 + ) ( b ), Treg cells (CD45 + CD4 + FOXP3 + ) ( c ), MDSCs (CD45 + CD11b + Gr-1 + ) ( d ), IFN-γ-secreting CD8 + T cells (CD45 + CD3 + CD8 + IFN-γ + ) ( e ), and CD8 + T cell proliferation (CD45 + CD3 + CD8 + Ki67 + ) ( f ) within the TME following the indicated treatments. g – i Quantification of the infiltration of CD45 + immune cells ( g ), CD4 + T cells ( h ), and CD8 + T cells ( i ) into lung tumors using flow cytometry. j – n ELISA analysis of IFN-γ ( j ), IL-2 ( k ), IL-12p70 ( l ), TNF-α ( m ), and IL-10 ( n ) levels in lung tumors of mice following the indicated treatments. Flow cytometry gating strategies are shown in Supplementary Fig. . All data are from n = 5 mice and are presented as mean ± s.d. Statistical analysis was performed using one-way ANOVA with Bonferroni’s multiple comparisons test. P values as indicated. Source data are provided as a Source Data file.

Article Snippet: The isolated CD8 T cells were resuspended in RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin, and 0.1% 2-mercaptoethanol (Thermo Fisher Scientific) and then cultured in a 48-well plate pretreated with anti-mouse CD3 and CD28 antibodies (Bio X Cell).

Techniques: Flow Cytometry, Enzyme-linked Immunosorbent Assay